Tirzepatide e Mounjaro: the molecule, the medicine and what comes in the box

Step 1: understanding what tirzepatide actually is

Tirzepatide is a synthetic peptide designed to mimic two gut hormones simultaneously, glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). Both hormones are released naturally after eating; they signal fullness to the brain, slow the rate at which the stomach empties, and help regulate blood sugar. Most GLP-1 medicines target only the second pathway. Tirzepatide targets both, which is why researchers and regulators describe it as a dual agonist and why its trial results differ from those of single-pathway alternatives.

Eli Lilly developed tirzepatide and obtained UK marketing authorisation under the brand name Mounjaro for two indications: weight management in adults with a BMI of 30 or above (or 27 or above with at least one weight-related health condition), and type 2 diabetes. The NHS medicines page for tirzepatide covers the pharmacology and common side effects in plain English if you want the patient-level detail. When you see Mounjaro on a box or a pharmacy website, tirzepatide is the substance inside it, the brand name adds nothing clinically distinct.

The SURMOUNT-1 trial, published in the New England Journal of Medicine, randomised 2,539 adults with obesity and reported average body-weight reductions of around 20–21% at the 15 mg dose over 72 weeks. That scale of evidence is why the wider tirzepatide story, including how it is licensed and supplied in the UK, drew so much attention when NICE formally appraised it.

Step 2: how the prescribing process works in the UK

Because Mounjaro is a prescription-only medicine, the legal starting point is clinical assessment, a prescriber reviews your health history, current medicines, BMI and relevant conditions before deciding whether to issue a prescription. No pharmacy in the UK can dispense it any other way, and any seller offering it without that step is operating outside the law.

At nume, the sequence is straightforward. You complete a free online consultation; a GPhC-registered Independent Prescriber (a real clinician, not automated software) reads your answers the same day. If treatment is clinically suitable, the prescription is issued and the order dispatched. If you place your order before noon on a working day, dispatch happens that afternoon. A DPD notification arrives on your phone, and the next working day a plain, unbranded box appears at your door containing the Mounjaro KwikPen, the Patient Information Leaflet and everything you need to start. If you have come across e-Mounjaro, which refers to the electronic prescribing and online supply route, that is the process described here. For anyone weighing up which medicine might suit their situation, our page comparing Mounjaro and tirzepatide by name addresses exactly that question, and this page on whether tirzepatide is Mounjaro goes further into the regulatory history.

Step 3: eligibility, doses and what happens after the first pen

Treatment starts at 2.5 mg, a starter dose whose job is to let the body adjust before any therapeutic increase, largely to keep early nausea manageable. The prescriber then titrates upward, typically in 4-week steps through 5, 7.5, 10, 12.5 and 15 mg, pausing at whichever dose works and is tolerated. Most people don't need the maximum.

Under NICE technology appraisal TA1026, tirzepatide is recommended on the NHS for adults with a BMI of 35 or above and at least one weight-related comorbidity; thresholds are 2.5 kg/m² lower for certain ethnic backgrounds. Private prescribing follows the licensed criteria, which set the bar at BMI 30 (or 27 with a qualifying condition), so many people who don't meet NHS thresholds are still clinically eligible for private treatment. BMI alone never determines approval, the prescriber weighs the full picture.

Common side effects are gastrointestinal: nausea, loose stools, constipation and indigestion are the ones most frequently reported, and they tend to ease within a couple of weeks of each dose step. Serious events are uncommon but include acute pancreatitis, seek urgent medical attention for severe stomach pain that radiates to the back. The treatment is not used in pregnancy, during breastfeeding, or when trying to conceive, and it is not licensed for anyone under 18.

If cost is a factor in your thinking, the Mounjaro cost page sets out how UK private pricing is structured and what a legitimate prescription price typically includes. For a broader look at all licensed weight-loss options, our treatment overview is a good place to start before the consultation.